Reaction

Urinary Tract Infection Bacterial reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,477 reports · 98 co-occurring drugs

As of the last recalculation, Urinary Tract Infection Bacterial appears in 2,477 FAERS reports alongside 98 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 39.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Infliximab-Dyyb	131	39.7	39.9
Alemtuzumab	67	29.9	30.0
Anti-Thymocyte Globulin (Rabbit)	24	25.2	25.3
Valganciclovir Hydrochloride Powder,	25	17.4	17.4
Busulfan	32	17.3	17.3
Basiliximab	23	16.6	16.6
Dimenhydrinate	19	15.1	15.1
Valganciclovir	33	14.9	14.9
Valganciclovir Hydrochloride	33	14.9	14.9
Micafungin Sodium	13	12.9	13.0
Nitrofurantoin	25	12.9	12.9
Nitrofurantoin (Monohydrate/Macrocrystals)	25	12.7	12.7
Thiotepa	14	12.4	12.4
Tacrolimus Extended-Release Capsules	172	12.4	12.4
Tacrolimus Ointment 0.1%	170	12.2	12.3
Everolimus Tablets	24	12.1	12.2
Bendamustine Hydrochloride	17	12.0	12.0
Mycophenolate Mofetil	181	12.0	12.0
Mycophenolate Mofetil Hydrochloride	181	12.0	12.0
Tacrolimus	205	11.9	11.9
Cefuroxime	16	11.8	11.8
Ganciclovir Sodium	14	11.2	11.2
Obinutuzumab	21	10.8	10.8
Ganciclovir	13	10.7	10.7
Tofacitinib Citrate	15	9.7	9.7
Mycophenolic Acid	34	9.0	9.0
Fludarabine Phosphate	41	8.9	8.9
Methylprednisolone	135	8.6	8.6
Mycophenilic Acid	21	8.6	8.6
Tizanidine Hydrochloride	18	8.4	8.4
Methylprednisolone Acetate	8	8.4	8.4
Cefepime	14	8.2	8.3
Trimethoprim	11	7.9	7.9
Cefepime Hydrochloride	15	7.9	7.9
Torsemide	30	7.7	7.7
Docusate Sodium - Sennosides	29	7.6	7.6
Oxybutynin	26	7.5	7.5
Isosorbide Dinitrate	17	7.4	7.4
Atovaquone	7	7.3	7.3
Granisetron Hydrochloride	9	7.3	7.3
Mirabegron	33	7.3	7.3
Dalfampridine	60	7.2	7.2
Ocrelizumab	52	7.2	7.2
Cladribine	8	7.0	7.0
Polyethylene Glycol	9	7.0	7.0
Ciprofloxacin Hydrochloride And Hydrocortisone	17	6.9	6.9
Mometasone	15	6.9	6.9
Baclofen	68	6.8	6.8
Oxybutynin Chloride	7	6.7	6.7
Sirolimus	10	6.3	6.3
Pegaspargase	9	6.2	6.2
Filgrastim	27	6.1	6.1
Bendamustine Hcl	11	6.0	6.0
Eculizumab	36	5.6	5.6
Naproxen Sodium Tablet, Coated	9	5.6	5.6
Naproxen Sodium, Coated Tablets	9	5.6	5.6
Naproxen Sodium 220Mg	9	5.6	5.6
Progesterone	15	5.5	5.5
Triamcinolone Acetonide Ointment Usp, 0.05%	15	5.4	5.4
Etonogestrel And Ethinyl Estradiol	14	5.3	5.3
Gemcitabine Hydrochloride	32	5.1	5.1
Azacitidine For	11	5.1	5.1
Mesna Injection	5	5.1	5.1
Aprepitant	11	5.0	5.0
Mesna	5	5.0	5.0
Gemcitabine	23	4.9	4.9
Etoposide	41	4.7	4.8
Brivaracetam	5	4.7	4.7
Everolimus	28	4.7	4.7
Daratumumab	22	4.7	4.7
Cyclophosphamide Injection, Solution	95	4.6	4.7
Cyclophosphamide	95	4.6	4.7
Cyclophosphamide For Injection	95	4.6	4.7
Azacitidine	16	4.6	4.6
Cisplatin	40	4.4	4.4
Lanreotide Acetate	4	4.3	4.3
Cytarabine	30	4.2	4.2
Carfilzomib	14	4.2	4.2
Empagliflozin	33	4.2	4.2
Cenobamate	4	4.0	4.0
Ruxolitinib	34	4.0	4.0
Dofetilide	5	4.0	4.0
Romiplostim	7	3.9	3.9
Dapagliflozin	14	3.8	3.8
Ravulizumab	6	3.7	3.7
Canagliflozin	13	3.7	3.7
Droxidopa	9	3.5	3.5
Deferasirox	11	3.5	3.5
Polatuzumab Vedotin	4	3.4	3.4
Tofacitinib	70	3.3	3.3
Bortezomib	34	3.2	3.2
Rifaximin	8	3.2	3.2
Vibegron	3	3.1	3.1
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	3	3.1	3.1
Siponimod	3	2.8	2.8
Enzalutamide	15	2.2	2.2
Pomalidomide	20	1.6	1.6
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	5	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.